CD6 Ectodomain Bacterial Aggregation for Sepsis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis, including antibacterials and recombinant human activated protein C, have limited efficacy, and there is a need for new approaches to intervene at multiple points in the sepsis cascade due to the high redundancy of molecular mediators involved in the sepsis response, leading to ongoing high morbidity and mortality.
Innovation Solution
The use of the ectodomain of human CD6, which binds to conserved microbial structures such as lipopolysaccharide and lipoteichoic acid, providing a high-affinity interaction that can abolish lethal effects of septic shock by inducing bacterial aggregation and reducing inflammatory responses, thereby enhancing survival rates and reducing pro-inflammatory cytokine levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (antibacterials, recombinant human activated protein C) are used for sepsis, then some therapeutic effect is achieved, but efficacy is limited and mortality remains high
Solution Approach 1:
The CD6 ectodomain provides a universal therapeutic approach that binds to conserved microbial structures (LPS from Gram-negative bacteria and LTA from Gram-positive bacteria) through a single molecule, enabling broad-spectrum activity against diverse pathogens. This multi-functional binding capability addresses the limitation of current treatments that target specific bacterial types or pathways
Solution Approach 2:
The CD6 ectodomain acts as an intermediary molecule that bridges the gap between pathogen recognition and immune modulation. It binds directly to microbial structures and simultaneously interacts with host cells (T cells, B cells, monocytes, macrophages, dendritic cells) to modulate immune responses, thereby mediating the therapeutic effect without requiring direct elimination of the pathogen
2Reliability
If new approaches are developed to intervene at multiple points in the sepsis cascade, then therapeutic potential increases, but device complexity and development difficulty increase
Solution Approach 1:
A single CD6 ectodomain molecule performs multiple therapeutic functions simultaneously: it binds to various microbial structures (LPS, LTA), aggregates bacteria, and modulates immune responses across multiple cell types. This multi-functionality in a single agent avoids the complexity of combining multiple separate therapies while achieving intervention at multiple points in the sepsis cascade
Solution Approach 2:
The invention merges pathogen recognition, bacterial aggregation, and immune modulation functions into a single CD6 ectodomain therapeutic agent. This consolidation simplifies the treatment approach compared to using separate agents for each function, while still achieving comprehensive intervention in the sepsis pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Administration of a recombinant form of CD6 significantly enhances survival rates in mice challenged with LPS-induced septic shock and concomitantly induces a significant reduction in serum levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6, demonstrating its therapeutic potential for septic shock and other inflammatory diseases.
Implementation Method 1
the ectodomain of human CD6, a cell surface receptor mainly expressed by cells of the lymphoid lineage, is able to bind to conserved microbial structures such as lipopolysaccharide (LPS) and lipotheicoic acid (LTA) from Gram-negative and Gram-positive bacteria, respectively
Implementation Method 2
i.p. administration of a recombinant form of CD6 abolishes the lethal effects caused by LPS-induced septic shock in mice
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2D
AI summary
The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of an infectious disease or of an inflammatory condition related to an infectious disease or to the presence of a product derived from an infectious agent in a mammal including a human. Examples of such inflammatory conditions are systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock.